Cargando…
First-line chemotherapy for ovarian cancer – the controversy continues
British Journal of Cancer (2002) 87, 813–814. doi:10.1038/sj.bjc.6600568 www.bjcancer.com © 2002 Cancer Research UK
Autor principal: | Kaye, S B |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376182/ https://www.ncbi.nlm.nih.gov/pubmed/12373592 http://dx.doi.org/10.1038/sj.bjc.6600568 |
Ejemplares similares
-
First-line treatment of ovarian cancer: questions and controversies to address
por: Ledermann, Jonathan A.
Publicado: (2018) -
Chemotherapy for ovarian cancer: yesterday, today and tomorrow
por: Kaye, S B
Publicado: (2003) -
Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer
por: Vasey, P A, et al.
Publicado: (2001) -
Chemotherapy for ovarian cancer--trials, controversies and funding.
por: Hawkins, R. E.
Publicado: (1998) -
Controversy continues following final NICE guidelines update
por: Dalman, Ronald L.
Publicado: (2020)